Novo Nordisk announces breakthrough treatment for brain haemorrhage  

2004.06.23
Healthcare company Novo Nordisk has achieved a major breakthrough with NovoSeven in the treatment of brain haemorrhage

Healthcare company Novo Nordisk has achieved a major breakthrough with NovoSeven in the treatment of brain haemorrhage. Novo Nordisk yesterday announced the first results of a new clinical trial in which NovoSeven was tested in patients suffering from brain haemorrhage. The study demonstrated that the growth of haematoma in the group treated with NovoSeven was significant reduced in comparison to the placebo group.

 

The results also showed that patients treated with NovoSeven had a significantly improved neurological and functional outcome, promising a lasting patient benefit in terms of reduced disability and dependence on help. Lars Rebien Sørensen, managing director of Novo Nordisk, calls the results from the trial ground-breaking. The key results will be presented at the 5th World Stroke Congress in Vancouver, Canada, on Saturday 26 June. The news is reported by national newspaper Jyllands-Posten and in a press release from Novo Nordisk.

 

Novo Nordisk employs approx. 18,800 people in 69 countries and markets its products in 179 countries.

 

Link > Novo Nordisk 

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×